Key result
Percutaneous LAAO provides globally recognized stroke prevention in nonvalvular AF with decreasing complication rates.
Why the study?
Percutaneous left atrial appendage occlusion was developed to protect against stroke in nonvalvular AF, prompting an overview of available and investigational catheter-based occlusion devices, implantation techniques, and clinical trial evidence.
This review highlights the evolution, safety improvements, and potential future expansion of indications for percutaneous left atrial appendage occlusion devices in patients with nonvalvular atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Supports wider LAAO use in nonvalvular AF; leaves open expansion of indications pending prospective trials.
Obeid et al. (2020) conducted a review in Nonvalvular atrial fibrillation. Percutaneous left atrial appendage (LAA) occlusion devices was evaluated. Percutaneous left atrial appendage occlusion has become a globally recognized procedure for stroke prevention in patients with nonvalvular atrial fibrillation, with decreasing complication rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: